Table 1

Demographic, clinical and therapeutic data at the time of an enrollment in IORRA and at the time of measurement of serum 25(OH)D concentration
Factor At the time of enrollment in IORRA (nā€‰=ā€‰1957) At the time of measurement of serum 25(OH)D concentration (spring 2011, nā€‰=ā€‰899)
Age, years 57.5 (49.5 to 64.6) 64.3 (56.7 to 70.6)
Sex, female 1668 (85.2) 766 (87.7)
Duration of disease, years 7.0 (2.0 to 14.0) 16.0 (11.0 to 23.0)
BMI, kg/m2 21.2 (19.4 to 23.3) 21.2 (19.2 to 23.2)
DAS28 4.2 (3.3 to 5.0) 3.0 (2.4 to 3.8)
J-HAQ 0.8 (0.2 to 1.4) 0.6 (0.1 to 0.8)
RF, positive 1531 (81.8) 698 (80.0)
History of smoking, ever 641 (34.5) 235 (28.4)
History of TKR, ever 85 (4.3) 178 (20.4)
DMARDs use, ever 1670 (85.3) 777 (89.0)
Methotrexate use, ever 792 (40.8) 638 (73.1)
Biologic use, ever 12 (0.6) 155 (17.8)
Corticosteroid use, ever 932 (47.6) 399 (45.7)
Bisphosphonate use, ever 63 (3.2) 280 (32.1)
Active vitamin D use, ever 61 (3.1) 112 (12.8)
Serum total protein level, g/dL Data not available 7.3 (7.0 to 7.6)
Serum total cholesterol level, mg/dL Data not available 209.0 (188.0 to 231.0)
Serum alkaline phosphate level, IU/L Data not available 258.0 (213.0 to 321.2)
NSAIDs use, ever Data not available 515 (59.0)

Data are presented as median (IQR) or n (%). IORRA, Institute of Rheumatology, Rheumatoid Arthritis cohort; BMI, body mass index; DAS28, disease activity score in 28 joints; J-HAQ, Japanese version of the Health Assessment Questionnaire; RF, rheumatoid factor; TKR, total knee replacement; DMARD, disease modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug.

Yoshida et al.

Yoshida et al. Arthritis Research & Therapy 2014 16:R75   doi:10.1186/ar4516

Open Data